Synthetic galectin-3 inhibitor increases metastatic cancer cell sensitivity to taxol-induced apoptosis in vitro and in vivo

Neoplasia

Volumn 11, Issue 9, 2009, Pages 901-909

  Glinsky, Vladislav V ^a,b,d   Kiriakova, Galina ^c   Glinskii, Olga V ^a,b   Mossine, Valeri V ^b   Mawhinney, Thomas P ^b   Turk, James R ^d   Glinskii, Anna B ^e,f   Huxley, Virginia H ^b   Price, Janet E ^c   Glinsky, Gennadi V ^e,f,g  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b University of Missouri   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d UNIVERSITY OF MISSOURI   (United States)

^e ALBANY MEDICAL COLLEGE   (United States)

^f ORDWAY RESEARCH INSTITUTE   (United States)

^g Ordway Research Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GALECTIN 3; LACTULOSYL LEVO LEUCINE; PACLITAXEL; PROTEIN BCL 2; PROTEIN INHIBITOR; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ADVANCED CANCER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER MODEL; CELL SURVIVAL; CHEMOSENSITIVITY; CLONOGENESIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; IC 50; LUNG METASTASIS; METASTASIS INHIBITION; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BLOTTING, WESTERN; BREAST NEOPLASMS; DRUG COMBINATIONS; GALACTOSIDES; GALECTIN 3; HUMANS; LEUCINE; LUNG NEOPLASMS; MEMBRANE POTENTIAL, MITOCHONDRIAL; PACLITAXEL; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR CELLS, CULTURED; TUMOR STEM CELL ASSAY;

EID: 69249103709     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.09594     Document Type: Article

References (24)

1. Pommier Y, Sordet O, Antony S, Hayward RL, and Kohn KW (2004). Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks. Oncogene 23, 2934-2949.
2. Reed JC (2003). Apoptosis-targeted therapies for cancer. Cancer Cell 1, 17-22.
3. Li R, Boehm AL, Miranda MB, Shangary S, Grandis JR, and Johnson DE (2007). Targeting antiapoptotic Bcl-2 family members with cell-permeable BH3 peptides induces apoptosis signaling and death in head and neck squamous cell carcinoma cells. Neoplasia 9, 801-811.
4. Kock N, Kasmieh R, Weissleder R, and Shah K (2007). Tumor therapy mediated by lentiviral expression of shBcl-2 and S-TRAIL. Neoplasia 9, 435-442.
5. Hetschko H, Voss V, Senft C, Seifert V, Prehn JH, and Kögel D (2008). BH3 mimetics reactivate autophagic cell death in anoxia-resistant malignant glioma cells. Neoplasia 10, 873-885.
6. Akahani S, Nangia-Makker P, Inohara H, Kim H-RC, and Raz A (1997). Galectin-3: a novel antiapoptotic molecule with a functional BH1 (NWGR) domain of Bcl-2 family. Cancer Res 57, 5272-5276.
7. Yu F, Finley RL, Raz A, and Kim H-RC (2002). Galectin-3 translocates to the perinuclear membranes and inhibits cytochrome c release from the mitochondria. J Biol Chem 277, 15819-15827.
8. Yin X-M, Oltavi ZN, and Korsmeyer SJ (1994). BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax. Nature 369, 321-323.
9. Fukumori T, Ok N, Takenaka Y, Nangia-Makker P, Elsamman E, Kasai T, Shono M, Kanayama HO, Ellerhorst J, Lotan R, et al. (2006). Galectin-3 regulates mitochondrial stability and antiapoptotic function in response to anticancer drug in prostate cancer. Cancer Res 66, 3114-3119.
10. Glinsky VV, Glinsky GV, Rittenhouse-Olsen K, Huflejt ME, Glinskii OV, Deutscher SL, and Quinn TP (2001). The role of Thomsen-Friedenreich antigen in adhesion of human breast and prostate cancer cells to the endothelium. Cancer Res 61, 4851-4857.
11. Glinsky GV, Price JE, Glinsky VV, Mossine VV, Kiriakova G, and Metcalf JB (1996). Inhibition of human breast cancer metastasis in nude mice by synthetic glycoamines. Cancer Res 56, 5319-5324.
12. Price JE, Polyzos A, Zhang RD, and Daniels LM (1990). Tumorigenicity and metastasis of human breast carcinoma cell lines in nude mice. Cancer Res 50, 717-721.
13. Price JE, Zhang FA, Radinsky RD, and Pathak SR (1994). Characterization of variants of a human breast cancer cell line isolated from metastases in different organs of nude mice. Int J Oncol 5, 459-467.
14. Rae JM, Ramus SJ, Waltham M, Armes JE, Campbell IG, Clarke R, Barndt RJ, Johnson MD, and Thompson EW (2004). Common origins of MDAMB-435 cells from various sources with those shown to have melanoma properties. Clin Exp Metastasis 21, 543-552.
15. Glinsky GV, Mossine VV, Price JE, Bielenberg D, Glinsky VV, Ananthaswamy HN, and Feather MS (1996). Inhibition of colony formation in agarose of metastatic human breast carcinoma and melanoma cells by synthetic glycoamine analogs. Clin Exp Metastasis 14, 253-267.
16. Glinsky VV, Glinsky GV, Glinskii OV, Huxley VH, Turk JR, Mossine VV, Deutscher SL, Pienta KJ, and Quinn TP (2003). Intravascular metastatic cancer cell homotypic aggregation at the sites of primary attachment to the endothelium. Cancer Res 63, 3805-3811.
17. Johnson KD, Glinskii OV, Mossine VV, Turk JR, Mawhinney TP, Anthony DC, Henry CJ, Huxley VH, Glinsky GV, Pienta KJ, et al. (2007). Galectin-3 as a potential therapeutic target in tumors arising from malignant endothelia. Neoplasia 9, 662-670.
18. Srivastava RK, Mi QS, Hardwick JM, and Longo DL (1999). Deletion of the loop region of Bcl-2 completely blocks paclitaxel-induced apoptosis. Proc Natl Acad Sci USA 96, 3775-3780.
19. Shitashige M, Toi M, Yano T, Shibata M, Matsuo Y, and Shibasaki F (2001). Dissociation of Bax from a Bcl-2/Bax heterodimer triggered by phosphorylation of serine 70 of Bcl-2. J Biochem 130, 741-748.
20. Li C, Price JE, Milas L, Hunter NR, Ke S, Yu DF, Charnsangavej C, and Wallace S (1999). Antitumor activity of poly(L-glutamic acid)-paclitaxel on syngeneic and xenografted tumors. Clin Cancer Res 5, 891-897.
21. Pienta KJ, Naik H, Akhtar A, Yamazaki K, Replogle TS, Lehr J, Donat TL, Tait L, Hogan V, and Raz A (1995). Inhibition of spontaneous metastasis in a rat prostate cancer model by oral administration of modified citrus pectin. J Natl Cancer Inst 87, 348-353.
22. Nangia-Makker P, Hogan V, Honjo Y, Baccarini S, Tait L, Bresalier R, and Raz A (2002). Inhibition of human cancer cell growth and metastasis in nude mice by oral intake of modified citrus pectin. J Natl Cancer Inst 94, 1854-1862.
23. Inohara H and Raz A (1994). Effects of natural complex carbohydrate (citrus pectin) on murine melanoma cell properties related to galectin-3 functions. Glycoconj J 11, 527-532.
24. Chauhan D, Li G, Podar K, Hideshima T, Neri P, He D, Mitsiades N, Richardson P, Chang Y, Schindler J, et al. (2005). A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells. Cancer Res 65, 8350-8358.